Respiratory Diseases

Merck Collaborates with Dewpoint Therapeutics to Cure HIV with Condensates   Merck has forged a collaboration with Boston-based Dewpoint Therapeutics to treat HIV using Dewpoint’s proprietary platform for condensate-based drug discovery.Under the terms of the agreement, Dewpoint is eligible for receiving up to an upfront amount of USD 305 Million along with milestone payments as well as royalties on sales of products. Dewpoint was launched last year to explore and uncover novel mechanisms to treat one of the most devastating diseases - HIV. Dewpoint’s condensate platform explores the ability of condensates in curing HIV. Earlier Dewpoint also announced...